At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. We are determined to change the unacceptable reality that each year more than 42,000 women and men in the U.S. will die from breast cancer (BC). There exists a critical need for increasing our understanding of metastatic breast cancer (MBC) and developing new ways to treat those living with the disease to help them live longer, better lives.
About the Initiative
There is no doubt that the need for translational research into the understanding, detection, treatment, and strategic interventions regarding breast cancer mortality is urgent. The Susan G. Komen® Metastatic Breast Cancer Collaborative Research Initiative will target and fund collaborative efforts between researchers at Duke University, and the University of North Carolina Chapel Hill. These institutions are making significant progress independently towards understanding and solving the devastating consequences of MBC. This new Komen-driven initiative will catalyze collaborations, bringing together the best and brightest researchers at these institutions to share ideas, expertise and resources to conquer MBC.
MBC Collaborative Research Virtual Summit, Sponsored by Biologics by McKesson
Susan G. Komen® is excited to kick off this initiative with the MBC Collaborative Research Summit sponsored by Biologics by McKesson, held virtually on February 19, 2021. Investigators from Duke University and the University of North Carolina Chapel Hill are invited to attend! Participants will:
- Learn about Komen’s new MBC Collaborative Research Grant funding opportunity
- Hear valuable perspectives from MBC patients
- Learn what researchers at both institutions are doing to end MBC
- Meet potential collaborators to expand and develop new ideas for approaches to MBC
“It is research that will cure this disease, and until then, it is research that will give patients and their families the priceless gift of time.”
– Ms. Pam Kohl, MBC Patient Advocate , Developmental Director for MBC Research Initiative
MBC Collaborative Research Grants
Through this new initiative, Susan G. Komen will award research grants to support collaborative research projects aimed at finding breakthrough discoveries to end metastatic breast cancer. Specifically, the program will support collaborative research projects focused on:
- Development of novel treatment strategies for existing metastatic disease,
- Strategies to prevent or arrest metastasis and late recurrence,
- Innovative approaches to detect new or recurrent metastatic breast cancer as early as possible before standard symptoms may be detectable,
- Investigations into biologic, behavioral, social and systems contributing to higher burden of late-stage (metastatic) breast cancer in the African American population
Thanks to a Leadership gift from Blue Cross and Blue Shield of North Carolina (Blue Cross NC) we are proud to announce the Susan G. Komen and Blue Cross NC Metastatic Breast Cancer Disparities Collaborative Research Grant focused on MBC disparities in Blacks will be awarded as part of this initiative.
More details about this new Komen research grant program and how to apply will be shared at the Virtual Summit.
Today, the five year survival rate for metastatic breast cancer is only twenty five percent. There is critical need for increasing our understanding of metastatic breast cancer and developing new ways to treat those living with the disease to help them live longer, better lives.
We have a unique opportunity in the Triangle area to support innovative research through a unique collaboration between Duke University and the University of North Carolina at Chapel Hill. This approach can lead to the very breakthroughs needed to change outcomes and save lives.”
– Victoria Wolodzko, Senior Vice President of Mission at Susan G. Komen
Thank you to our sponsor of the virtual summit:
Thank you to our Leadership Donor: